The market for diabetes + hyperlipidemia complex is going nowhere.
According to the recent trend of the outpatient report, the size of the diabetes + hyperlipidemia complex market reached KRW 218.14 million (USD 190,798) in August.
Although this is a 15.3% increase from the same period last year, it is a 12% decrease from July, KRW 248.78 million (USD 217,598).
The cumulative prescription amount for eight months was KRW 1.9254 billion (USD 1.663 million), an increase of 69.8% YoY, approaching the KRW 2 billion.
Rosumet (Yuhan) made KRW 53.5 million (USD 46,860) in August, ahead of LipitorM (Pfizer).
Lipitor M became the second-best with KRW 52.08 million (USD 45,556).
Zemiro (LG Chem) recorded KRW 36.62 million (USD 32,035), followed by Lipimet (Dae Woong) KRW 28.14 million (USD 24,617), Atomet (HK inno.N) KRW 22.21 million (USD 19,429), Rosutanmet (Dong Kook) KRW 11.62 million (USD 10,168), Crevis (KUKJE PHARM) KRW 10.84 million (USD 9,485), and Duo Met-XR (Jeil Pharm) KRW 3.06 million (USD 2,677).
LipitorM led the eight-month cumulative prescription amount by KRW 620.21 million (USD 542,805). Following behind were Rosumet with KRW 389.81 million (USD 341,041), Zemiro KRW 301.1 million (USD 263,429), Atomet KRW 254.76 million (USD 222,848), and Lipimet KRW 217.41 million (USD 190,176), exceeding KRW 100 million.
In addition, Crevis was found to be KRW 75.03 million (USD 65,643), Rosutanmet KRW 40,56 million (USD 35,485), and Duo Met-XR KRW 3.06 million (USD 2,677).
